Franklin Templeton’s Notes from the Trading Desk offers a weekly overview of what their professional traders and analysts are watching in the markets. The European desk is manned by eight professionals based in Edinburgh, Scotland, with an average of 15 years of experience whose job it is to monitor the markets around the world. Their views are theirs alone and are not intended to be construed as investment advice.
Last week many equity markets again advanced as investors appeared relaxed around inflationary pressures, and dovish rhetoric from central banks eased any nerves caused by stronger macro data. Last Thursday, the focus was on the US Consumer Price Index (CPI) data and the European Central Bank (ECB) meeting. The MSCI World Index traded up 0.5%, the STOXX Europe 600 Index +1.1%, the S&P 500 Index+0.4%, and the MSCI Asia Pacific Index, -0.2%.
Inflation Remains the Key Talking Point
As has been the case for much of 2021, the debate over rising inflationary pressures and the reaction from central banks dominated headlines last week as we had key US inflation data and an ECB meeting.
US CPI data came in at +5.0% year-on-year (y/y), which was the largest annual gain since August 2008. Core CPI (excluding food and energy) was at the highest level since 1992.
However, looking into the numbers, there did appear to be temporary factors driving this, something that tied in with the Federal Reserve’s (Fed) recent narrative that the current inflation surge is “transitory.” Within the data, “previously owned cars and trucks” accounted for about one-third of the total monthly advance, which is being driven by the chip shortage which should eventually correct itself. Air travel was also a factor, due to the reduced capacity that airlines are running. Finally, there was a slower month-on-month (m/m) pace of increase, with headline CPI up 0.6%, and excluding food and energy up 1.1%. There do seem to be some signs inflation could be easing.
Given the presence of some temporary factors driving inflation data, the markets are telling us investors are happy to run with the Fed’s narrative that inflationary pressures are transitory. We see this view reflected across asset classes. US equity markets remain near all-time highs and US bond yields tightened last week, with the US 10-year Treasury yield at 1.49%, its lowest level in three months. Often a “canary in the coal mine,” credit markets are not showing signs of stress either, with high-yield spreads remaining tight.
This Wednesday we have the June Fed meeting, so we will have further clarity on Chair Jerome Powell’s thinking. However, with steady performance across asset classes it feels like investors are not expecting much of a change in tone. Looking ahead, the key dates may be the central bankers’ summit in Jackson Hole, Wyoming, at the end of the summer, and the September Fed meeting.
ECB Remains Dovish Despite Improving Picture
The ECB stuck with its accommodative stance last week, keeping policy unchanged despite an improving economic outlook for the region. Interest rates stayed on hold and the ECB stated that the pandemic emergency purchase programme (PEPP) asset purchases would be significantly greater than the first quarter (as stated before) and around the current pace of €20 billion a week (in line with expectations).
In terms of outlook, the ECB now projects a “sizeable improvement in activity in the second quarter” followed by further robust recovery in the second half of the year. The central bank sees gross domestic product (GDP) of 4.6% (up from 4.0% in the March projections) for 2021 and 4.7% (instead of 4.1%) for 2022. The ECB now expects 1.9% (instead of 1.5%) for 2021 and 1.5% (up from 1.2%) for 2022. For 2023, the ECB left its call unchanged at 1.4%. These predictions are below its 2% target for inflation.
Last week also saw positive outlook from Germany’s Bundesbank, which upgraded its growth forecasts to 3.7% this year versus prior 3.0% estimate, and 5.2% for 2022 versus 4.5% prior.
This sets up a supportive backdrop for European equity markets and, with the European Recovery Fund due to impact in the second half of the year, many investment banks continue to push European equities, noting rising vaccination rates should support economic activity as the European Recovery Fund kicks in.
The Week in Review
This week saw European equities grind higher to make fresh all-times highs, with the STOXX Europe 600 Index up 1.1%. This was the fourth consecutive week of gains. Once again, European equities outperformed other regions, with continued focus on an improving macro backdrop thanks to accelerating European vaccination programs, declining COVID-19 cases (excluding the United Kingdom) and the imminent distribution of the European Recovery Fund. With that, European equities saw a ninth straight week of inflows. The main talking point was last Thursday’s ECB meeting which saw accommodative policies remain on hold, despite a more optimistic outlook.
Health care outperforms: There was a less familiar look to sector performance. Health care stocks had a rare day in the sun as this sector has been a major underperformer over the past year for well-documented reasons. It felt like the Biogen Alzheimer drug news was a catalyst for some to look at the sector, particularly considering the underperformance. Tighter US yields this week have also helped. The feedback is that a lot of faster money is chasing the space this week given it is a big underweight, so it remains to be seen whether the move has legs to last longer.
Resources, chemicals and banks were the laggards on the week, with headwinds in tightening yields and the ECB remaining accommodative for banks. The banking sector remains second best year-to-date (automobiles are in the lead) so an element of investor profit- taking isn’t a surprise.
From a country perspective, Switzerland’s equity market was an outperformed thanks to health care strength. Italy’s FTSE MIB Index broke out to levels not since the 2008 global financial crisis last, as optimism regarding Italian equities grows.
The German DAX was left behind last week with meagre gains of 0.3% as the reflation trade ran out of steam. A clear example of this dynamic was the Goldman Sachs EU Reflation basket, which was one of the worst performing factors last week, down 0.4%.
In the United Kingdom, we continue to see decent macro data, with the UK economy growing 2.3% in April m/m (in line with expectations). However, it is worth keeping an eye on the rising COVID-19 cases driven by the new Indian/Delta variant, which is 40% more transmittable. The United Kingdom reported 8,125 more COVID-19 cases last Friday vs. an average 2,000 a day around a month ago. This wave will be a key test for the vaccination programme and whether the country can succeed in breaking the link between rising cases and hospitalisations.
Numbers in hospital are still low but edging higher, so it looks likely the further easing planned for UK lockdown on 21 June will be pushed out by about four weeks. The market feels relaxed that reopening will continue steadily, and we won’t see a return to lockdowns, so any shocks here could see sharp pull backs for reopening names.
The S&P 500 Index edged higher in what was a quiet week aside from the noise around the CPI data last week. Evidence of this muted performance is the limited number of days with moves over 1% in recent months.
Looking at sector performance, health care outperformed (+1.9%) thanks to the strength in Biogen. Financials lagged (-2.4%) as yields tightened.
In last week’s update, we highlighted some data around the improving finances of the average US household and how that could boost the US economy. On Thursday, the Fed released data that showed the net worth of US households climbed to new heights as 2021 began and the effects of the COVID-19 pandemic began to fade. Thanks largely to a surge in the stock market, the total balance sheet for households and non-profits rose to US$136.9 trillion in the first quarter, a 3.8% gain from the end of 2020, according to the Fed.
The G7 summit, held in the United Kingdom last week, was notable. We saw high levels of engagement from the United States, a sharp contrast to the prior administration. Much of the focus was on climate change and efforts to counter the influence of China.
Asia and Pacific
Last week was quiet for Asian markets with the MSCI Asia Pacific Index down 0.2%. Index performance was tightly grouped with the Japanese Nikkei unchanged, Shanghai Composite down 0.1% and the Hang Seng down 0.3%.
In Japan, the focus is on the vaccination program where the pace has picked up. With that, the reopening theme was back in play with sectors like transport, real estate, and land transport showing strong gains. We also had Japan’s first-quarter gross domestic product down 1.0% quarter-on quarter.
The tone of the G7 conference was a focal point, as G7 nations took a strong stand against China’s economic aspirations and human rights practices. US President Joe Biden declared there’d been “plenty of action” on Beijing, including offering an alternative to the sweeping “Belt and Road” initiative.
That said, there were talks last week between China’s Minister of Commerce, Wang Wentao, and US Secretary of Commerce, Gina M. Raimondo. According to press reports, Wang and Raimondo stressed the importance of dialogue and communication between China and the United States in the business field and agreed to promote the healthy development of pragmatic cooperation on trade and investment while properly handling differences. The two sides also agreed to maintain communication in their working relationship.
The Week Ahead
It should be a quiet start to the week with a number of markets in Asia (including China) closed Monday. Focus for the week will no doubt be on the Fed meeting, which concludes on Wednesday. In Europe, Norway and Switzerland are set for monetary policy decisions.
In terms of macro data, UK and EU CPI data will be a focus, and European industrial production will be closely watched, too.
The Biden-Putin summit on Wednesday could provide us with some drama.
Monday 14 June
- Eurozone industrial production (IP)
Tuesday 15 June
- Germany CPI
- UK claimant count and International Labour Organisation unemployment rate
- France CPI
- Italy CPI EU harmonised
- Eurozone trade balance
- US Purchasing Managers’ Index (PPI) final demand
- US industrial and manufacturing production
Wednesday 16 June
- UK CPI & Retail Price Index (RPI)
- US FOMC Projections
- Chinese retail sales and IP
- Japanese trade balance
- US President Joe Biden will meet Russian President Vladimir Putin in Geneva
Thursday 17 June
- Norway policy rate decision
- Eurozone EU27 new car registrations
- Eurozone CPI core and construction output
- US Jobless claims
Friday 18 June
- UK retail sales
- Germany PPI
- ECB current account
- Japanese CPI
Franklin Templeton Key risks & Disclaimers:
What Are the Risks?
All investments involve risk, including possible loss of principal. The value of investments can go down as well as up, and investors may not get back the full amount invested. Stock prices fluctuate, sometimes rapidly and dramatically, due to factors affecting individual companies, particular industries or sectors, or general market conditions. Bond prices generally move in the opposite direction of interest rates. Thus, as prices of bonds in an investment portfolio adjust to a rise in interest rates, the value of the portfolio may decline. Investments in foreign securities involve special risks including currency fluctuations, economic instability and political developments. Investments in developing markets involve heightened risks related to the same factors, in addition to those associated with their relatively small size and lesser liquidity. Past performance is not an indicator or guarantee of future performance.
This article reflects the analysis and opinions of Franklin Templeton’s European Trading Desk as of 14th June 2021, and may vary from the analysis and opinions of other investment teams, platforms, portfolio managers or strategies at Franklin Templeton. Because market and economic conditions are often subject to rapid change, the analysis and opinions provided may change without notice. An assessment of a particular country, market, region, security, investment or strategy is not intended as an investment recommendation, nor does it constitute investment advice. Statements of fact are from sources considered reliable, but no representation or warranty is made as to their completeness or accuracy. This article does not provide a complete analysis of every material fact regarding any country, region, market, industry or security. Nothing in this document may be relied upon as investment advice or an investment recommendation. The companies named herein are used solely for illustrative purposes; any investment may or may not be currently held by any portfolio advised by Franklin Templeton. Data from third-party sources may have been used in the preparation of this material and Franklin Templeton (“FT”) has not independently verified, validated or audited such data. FT accepts no liability whatsoever for any loss arising from use of this information and reliance upon the comments, opinions and analyses in the material is at the sole discretion of the user. Products, services and information may not be available in all jurisdictions and are offered by FT affiliates and/or their distributors as local laws and regulations permit. Please consult your own professional adviser for further information on availability of products and services in your jurisdiction.
Issued by Franklin Templeton Investment Management Limited (FTIML) Registered office: Cannon Place, 78 Cannon Street, London EC4N 6HL. FTIML is authorised and regulated by the Financial Conduct Authority.
This information has been accurately reproduced, as received from Franklin Templeton Investment Management Limited (FTIML). No information has been omitted which would render the reproduced information inaccurate or misleading. This information is being distributed by MeDirect Bank (Malta) plc to its customers. The information contained in this document is for general information purposes only and is not intended to provide legal or other professional advice nor does it commit MeDirect Bank (Malta) plc to any obligation whatsoever. The information available in this document is not intended to be a suggestion, recommendation or solicitation to buy, hold or sell, any securities and is not guaranteed as to accuracy or completeness.
The financial instruments discussed in the document may not be suitable for all investors and investors must make their own informed decisions and seek their own advice regarding the appropriateness of investing in financial instruments or implementing strategies discussed herein.
If you invest in this product you may lose some or all of the money you invest. The value of your investment may go down as well as up. A commission or sales fee may be charged at the time of the initial purchase for an investment. Any income you get from this investment may go down as well as up. This product may be affected by changes in currency exchange rate movements thereby affecting your investment return therefrom. The performance figures quoted refer to the past and past performance is not a guarantee of future performance or a reliable guide to future performance. Any decision to invest in a mutual fund should always be based upon the details contained in the Prospectus and Key Investor Information Document (KIID), which may be obtained from MeDirect Bank (Malta) plc.